ISFM consensus guidelines on the practical management of diabetes mellitus in cats.
- Sparkes AH International Cat Care/ISFM, Tisbury, Wiltshire SP3 6LD, UK andy@icatcare.org.
- Cannon M Oxford Cat Clinic, Oxford OX2 9JU, UK.
- Church D Professor, Small Animal Medicine and Surgery Group, The Royal Veterinary College, North Mymms, Hatfield, Hertfordshire AL9 7TA, UK.
- Fleeman L Animal Diabetes Australia, Rowville Veterinary Clinic, Rowville, VIC 3178, Australia.
- Harvey A Small Animal Specialist Hospital, North Ryde, NSW 2113, Australia.
- Hoenig M Professor, Department of Veterinary Clinical Medicine, University of Illinois College of Veterinary Medicine, Urbana-Champaign, Illinois, USA.
- Peterson ME Animal Endocrine Clinic, 21 West 100th Street, New York, NY 10025, USA.
- Reusch CE Professor & Director, Clinic for Small Animal Internal Medicine, Vetsuisse Faculty, University of Zurich, Winterthurerstrasse 260, 8057 Zurich, Switzerland.
- Taylor S International Cat Care/ISFM, Tisbury, Wiltshire SP3 6LD, UK.
- Rosenberg D Micen Vet Centre, 58 Rue Auguste Perret, Parc Technologique, Europarc, 9400 Créteil, France.
- 2015-02-22
Published in:
- Journal of feline medicine and surgery. - 2015
Animals
Cat Diseases
Cats
Diabetes Mellitus, Type 2
Drug Administration Schedule
Hypoglycemic Agents
Insulin Detemir
Insulin, Long-Acting
International Agencies
Practice Guidelines as Topic
Societies, Medical
English
PRACTICAL RELEVANCE
Diabetes mellitus (DM) is a common endocrinopathy in cats that appears to be increasing in prevalence. The prognosis for affected cats can be good when the disease is well managed, but clinical management presents challenges, both for the veterinary team and for the owner. These ISFM Guidelines have been developed by an independent, international expert panel of clinicians and academics to provide practical advice on the management of routine (uncomplicated) diabetic cats.
CLINICAL CHALLENGES
Although the diagnosis of diabetes is usually straightforward, optimal management can be challenging. Clinical goals should be to limit or eliminate clinical signs of the disease using a treatment regimen suitable for the owner, and to avoid insulin-induced hypoglycaemia or other complications. Optimising bodyweight, feeding an appropriate diet and using a longer acting insulin preparation (eg, protamine zinc insulin, insulin glargine or insulin detemir) are all factors that are likely to result in improved glycaemic control in the majority of cats. There is also some evidence that improved glycaemic control and reversal of glucose toxicity may promote the chances of diabetic remission. Owner considerations and owner involvement are an important aspect of management. Provided adequate support is given, and owners are able to take an active role in monitoring blood glucose concentrations in the home environment, glycaemic control may be improved. Monitoring of other parameters is also vitally important in assessing the response to insulin. Insulin adjustments should always be made cautiously and not too frequently--unless hypoglycaemia is encountered.
EVIDENCE BASE
The Panel has produced these Guidelines after careful review of the existing literature and of the quality of the published studies. They represent a consensus view on practical management of cats with DM based on available clinical data and experience. However, in many areas, substantial data are lacking and there is a need for better studies in the future to help inform and refine recommendations for the clinical management of this common disease.
Diabetes mellitus (DM) is a common endocrinopathy in cats that appears to be increasing in prevalence. The prognosis for affected cats can be good when the disease is well managed, but clinical management presents challenges, both for the veterinary team and for the owner. These ISFM Guidelines have been developed by an independent, international expert panel of clinicians and academics to provide practical advice on the management of routine (uncomplicated) diabetic cats.
CLINICAL CHALLENGES
Although the diagnosis of diabetes is usually straightforward, optimal management can be challenging. Clinical goals should be to limit or eliminate clinical signs of the disease using a treatment regimen suitable for the owner, and to avoid insulin-induced hypoglycaemia or other complications. Optimising bodyweight, feeding an appropriate diet and using a longer acting insulin preparation (eg, protamine zinc insulin, insulin glargine or insulin detemir) are all factors that are likely to result in improved glycaemic control in the majority of cats. There is also some evidence that improved glycaemic control and reversal of glucose toxicity may promote the chances of diabetic remission. Owner considerations and owner involvement are an important aspect of management. Provided adequate support is given, and owners are able to take an active role in monitoring blood glucose concentrations in the home environment, glycaemic control may be improved. Monitoring of other parameters is also vitally important in assessing the response to insulin. Insulin adjustments should always be made cautiously and not too frequently--unless hypoglycaemia is encountered.
EVIDENCE BASE
The Panel has produced these Guidelines after careful review of the existing literature and of the quality of the published studies. They represent a consensus view on practical management of cats with DM based on available clinical data and experience. However, in many areas, substantial data are lacking and there is a need for better studies in the future to help inform and refine recommendations for the clinical management of this common disease.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1177/1098612X15571880
- PMID 25701862
- Persistent URL
- https://sonar.ch/global/documents/35687
Statistics
Document views: 150
File downloads:
- Full-text: 0